BASECARE-B (02170) signed a strategic cooperation agreement with RHEA LABS PTE. LTD to jointly expand the assisted reproductive industry market in the United States, Europe, South America, Southeast Asia and other regions.

BASECARE-B (02170) announced that its wholly owned subsidiary, Genea Biomedx Pty Ltd. (Genea Biomedx), a wholly owned subsidiary of BMX Holdco Pte. Ltd., entered into a strategic cooperation agreement with Rhea Labs Pte. Ltd. (Rhea Labs) on February 25, 2025. The strategic cooperation agreement, effective from the date of signing and lasting for five years, aims to leverage the synergies of the two parties' business advantages to jointly expand the market for the assisted reproductive industry in the United States, Europe, South America, and Southeast Asia, and to create benchmark IVF clinics empowered by artificial intelligence. According to the strategic cooperation agreement: (i) Genea Biomedx will provide high-quality medical products and comprehensive solutions to support Rhea Labs in the construction of reproductive institutions, covering overall solutions such as pre-implantation genetic testing (PGT) laboratories, embryo laboratories, andrology laboratories, cryogenic storage laboratories, as well as various types of assisted reproductive center equipment for various scenarios, including time-lapse incubators (Geri) and reproductive fluids (Gems); (ii) Rhea Labs and Genea Biomedx will jointly promote branding in the United States, Europe, and Southeast Asia; and (iii) Rhea Labs and Genea Biomedx will collaborate to develop new products based on artificial intelligence technology. Rhea Labs is a wholly owned subsidiary of Rhea Fertility, focusing on the exploration of digital technology in the field of assisted reproduction. Rhea Fertility mainly engages in assisted reproductive technology, gynecological endocrinology, and other services related to fertility, and is dedicated to promoting innovation in women's healthcare solutions and creating a globally integrated fertility business. The Board believes that the strategic cooperation agreement will enable the group to help expand the company's sales channels and strengthen its position in the assisted reproductive technology market, thus serving the overall interests of the company and its shareholders.